Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Study

Status: Ongoing

About

The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC (BURAN)


Details

The BURAN Study of Buparlisib (AN2025) In Combination With Paclitaxel Compared to Paclitaxel Alone, in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Sponsor: Adlai Nortye Biopharma Co

NCT04338399

Sponsors

HOPE Cancer Center

Hope Cancer Center

Contact

Contact UT Clinical
Scroll to Top